Navigation Links
Osbon ErecAid Vacuum Therapy System - Automatic

ProductsOsbon ErecAid Vacuum Therapy System - Automatic
Company Timm Medical Technologies, Inc.
Item Osbon ErecAid Vacuum Therapy System - Automatic
Features 
  • Restores sexual function in 9 out 10 men
  • Offers a non-invasive, drug-free alternative
  • Minimizes side effect risk
  • Provides an economical long-term solution
  • Is covered by Medicare and many insurance plans
Description Battery-driven vacuum system operates with a touch of a button.
Info Timm Medical Technologies, Inc.
Customer Service: (800) 438-8592
Web site: http://www.timmmedical.com

Related medicine products :

1. Osbon ErecAid Vacuum Therapy System - Manual
2. Osbon ErecAid Vacuum Therapy System - Classic
3. ErecAid® Esteem™ External Vacuum Therapy System
4. ACROBAT SUV Vacuum Off-Pump System
5. Iowa P.K. Press: Vacuum Suction Block
6. Terry-Schanzlin Astigmatome - Vacuum Speculum
7. Terry-Schanzlin Astigmatome - Vacuum Syringe
8. Optivac® Vacuum Mixing System
9. ULTRAMIX Vacuum Mixing System
10. UltraFit Coronet Vacuum Trephine
11. Vortex Vacuum Mixer
For rigid cystoscopes and rigid-, and semi-rigid ureteroscopes, these forceps have an integral handle design and a diameter of 5 Fr with a working length of 58 cm....
Fulgurating Electrode, 2 F...
Used to obtain biopsy specimens from pathological lesions in the ureter, renal pelvis, infundibula, or calyces. Supplied sterile in peel-open packages. Intended for one-time use....
Used to obtain tissue biopsy under direct vision. Cup Biopsy Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products:
(Date:6/19/2013)... 2013 Kleritec, Inc. announced the addition ... http://www.kleritec.com . In the recent expansion Kleritec ... activities packages for pre-school and day care providers. The ... to aid teachers across the United States the ability ... , Included in the art and activities packages is ...
(Date:6/19/2013)... York, NY (PRWEB) June 19, 2013 Citi Bike ... There’s no way for Dr. David Perna to know for sure ... service, but he’s happy that they’ll have the option. In ... healthier lives—especially if it might also make it more convenient for ... Dr. Perna is the Director of Complimentary Alternative Medicine at Back ...
(Date:6/19/2013)... a major international study led by researchers at The ... therapy ibrutinib continues to show remarkable promise for the ... , The most recent interim findings of the 18-center ... New England Journal of Medicine . Previous interim findings ... Society of Hematology Annual Meeting and Exposition. , ...
(Date:6/19/2013)... as many emergency department visits if their primary care ... days a week, according to new research from child ... Hopkins University. , The new study was published online ... and will be presented at the AcademyHealth Annual Research ... understanding where primary care practices and medical home programs ...
(Date:6/19/2013)... Nearly 70 percent of Americans are on ... half take two, Mayo Clinic researchers say. Antibiotics, ... their study found. Twenty percent of patients are ... the findings, published online in the journal ... audio and video of Dr. Jennifer St. Sauver ...
Breaking Medicine News(10 mins):Health News:Kleritec Announces Addition of Educational Products. 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2
... ... a workshop on Dried Blood Spot Sampling in the Pharmaceutical Industry: Methodology, Implementation and Best ... ... Drug Information Association (DIA) , in cooperation with PhRMA, will host a workshop on ...
... Fla., Nov. 13 Many Americans suffer from bipolar disorder ... there is another way to cope with the illness that ... of Darkness: A personal journey of embracing the bipolar opportunity" ... who was diagnosed bipolar at age 17 -- presents a ...
... CARY, N.C., Nov. 13 Cornerstone Therapeutics Inc. (Nasdaq ... developing and commercializing significant products primarily for the respiratory ... Andrew K. W. Powell, Esq. Executive Vice President, General ... will join the Company,s executive management team and manage ...
... ... published independent clinical study on Vemma, its physician formulated liquid supplement, ... (Volume 57, Number 19, October 14, 2009). The clinical study ... Product in Humans” found that Vemma is highly bioavailable, showing an ...
... ... for Wellbeing, the subscription course is aimed at optimizing health goals , ... Draper, UT (PRWEB) November 13, ... program called ZriiAware: Grow Younger, Live Longer , with the intention of helping ...
... PORTLAND, Ore. Nov. 12 Regence BlueCross BlueShield has ... the American Heart Association,s Start! movement for helping employees ... and employee wellness are important priorities at Regence," said ... providing the best workplace environment possible and helping our ...
Cached Medicine News:Health News:,DIA/PhRMA Workshop to Explore Dried Blood Spot Sampling Implementation and Advances, 2Health News:,DIA/PhRMA Workshop to Explore Dried Blood Spot Sampling Implementation and Advances, 3Health News:'Living Out of Darkness: A personal journey of embracing the bipolar opportunity' 2Health News:'Living Out of Darkness: A personal journey of embracing the bipolar opportunity' 3Health News:Cornerstone Therapeutics Appoints General Counsel 2Health News:Cornerstone Therapeutics Appoints General Counsel 3Health News:Independent Clinical Study Finds Vemma is Highly Bioavailable Showing Increase in Vitamins and Antioxidants in the Blood* 2Health News:Independent Clinical Study Finds Vemma is Highly Bioavailable Showing Increase in Vitamins and Antioxidants in the Blood* 3Health News:Independent Clinical Study Finds Vemma is Highly Bioavailable Showing Increase in Vitamins and Antioxidants in the Blood* 4Health News:Zrii Implements New Online Lifestyle Program, ZriiAware: Grow Younger, Live Longer 2Health News:Regence Recognized as an American Heart Association Start! Fit-Friendly Company 2Health News:Regence Recognized as an American Heart Association Start! Fit-Friendly Company 3
(Date:6/19/2013)... The Physician-Patient Alliance for Health & Safety recently released three ... urgently address this issue has been emphasized by The ... device alarm safety in hospitals." According to The Joint Commission ... there were 98 alarm related events reported, of which: ... resulted in permanent loss of function (13%) , 5 ...
(Date:6/19/2013)... NEW YORK , June 19, 2013   ... dedicated to finding a cure for brain cancer, today ... ) a grant to support the clinical investigation of ... a recurrent high grade glioma brain cancer (Grade 3 ... company developing novel treatments for advanced cancer, with an ...
(Date:6/19/2013)...   Nektar Therapeutics (Nasdaq: NKTR ) ... (HAL) study for NKTR-181, a first-in-class, opioid analgesic ... This slow rate of entry is designed to reduce the ... to current opioid analgesics. 1 In the study data ... placebo in "drug liking" and "feeling high" scores and had ...
Breaking Medicine Technology:Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 2Three Lessons Learned to Reduce Alarm Fatigue and Improve Alarm Management and Patient Safety in Hospitals 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9